Dimension Therapeutics Announces Participation in Two Upcoming Investor Conferences
Get Alerts DMTX Hot Sheet
Join SI Premium – FREE
CAMBRIDGE, Mass., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ: DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced that Dimension’s CEO Annalisa Jenkins, MBBS, MRCP, will participate in two upcoming investor conferences:
- Citi's 11th Annual Biotech ConferencePanel: Gene Therapy: A New EraWednesday, September 7, 2016 at 1:00 p.m. Eastern TimeThe Mandarin Oriental Hotel, Boston, MA
- 2016 Wells Fargo Healthcare ConferenceFireside Chat: Thursday, September 8, 2016 at 3:30 p.m. Eastern TimeThe Westin Boston Waterfront Hotel, Boston, MA
Live audio webcasts of the presentations can be accessed through the Investors section of the Company's website at www.dimensiontx.com. Replays of the webcasts will be available on the Company's website for two weeks following each presentation.
About Dimension Therapeutics
Dimension Therapeutics, Inc. (NASDAQ: DMTX) is the leader in discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver, based on the most advanced, mammalian adeno-associated virus (AAV) gene delivery technology. Dimension is actively progressing its broad pipeline, which features programs addressing unmet needs for patients suffering from inherited metabolic diseases, including OTC deficiency, GSDIa, citrullinemia type 1, PKU, Wilson disease, a collaboration with Bayer in hemophilia A, and a wholly owned clinical program in hemophilia B. The company targets diseases with readily identifiable patient populations, highly predictive preclinical models, and well-described, and often clinically validated, biomarkers. Founded in 2013, Dimension maintains headquarters in Cambridge, Massachusetts.
For more information, please visit http://www.dimensiontx.com.
CONTACT: Jean Franchi Chief Financial Officer Dimension Therapeutics 617-714-0709 [email protected] Burns McClellan, on behalf of Dimension Therapeutics Media: Justin Jackson 212-213-0006, ext.327 [email protected]Source: Dimension Therapeutics
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fosun Management on 2023 Annual Results: Focusing on Core Industries with Established Advantages
- Techtouch, Inc. ranks 8th in Technology Fast 50 2023 Japan, a ranking of fastest growing technology companies, with a 468.6% revenue growth rate
- BLUE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Bluebird bio Inc. and Encourages Investors to Contact the Firm
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Citi, Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!